Development and Production of membrane Proximal External Region (MPER)/ Anti-HIV broadly neutralizing antibodies (bNAbs) for prevention, therapy or cure

开发和生产用于预防、治疗或治愈的膜近端外部区域 (MPER)/抗 HIV 广泛中和抗体 (bNAb)

• 批准号: 9161852
• 负责人: MATT WESTERMAN
• 金额: $ 506.95万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-26 至 2020-09-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9161852
• 关键词: Area; Binding Sites; Breast Feeding; Clinic; Clinical; Development; Documentation; Epitopes; HIV; HIV Infections; HIV-1; Half-Life; Individual; Infant; Institutional Review Boards; Membrane; Mothers; Newborn Infant; Preclinical Testing; Prevention; Prevention therapy; Production; Prophylactic treatment; Reporting; Research; Sexual Transmission; Site; Therapeutic; Update; improved; meetings; neutralizing antibody; novel; research clinical testing; success; transmission process

Production and clinical testing of long half-life bNAbs targeting multiple neutralizing epitopes will improve the coverage and likely success of bNAbs for prophylaxis, therapy, and cure strategies. The VRC requires development and production of a bNAbs directed against an epitope other than CD4 binding site to ultimately combine with a CD4bs bNAb for prevention and treatment. Advances in this area will broadly impact strategies for: 1) prevention of transmission from HIV-1 infected mothers to newborn and breastfeeding infants; 2) prevention of HIV infection by sexual transmission; and 3) therapeutic application in HIV-1 infected individuals (including elimination of the latent reservoir). In the recent past, multiple research groups have identified and characterized novel broadly neutralizing antibodies directed against the MPER and other neutralization sites of HIV envelope. The VRC will development MPER mAbs and move them into the clinic, either alone or as part of combination approaches.

针对多个中和性表位的长半衰期bnab的生产和临床试验将提高bnab在预防、治疗和治愈策略中的覆盖率和成功率。VRC需要开发和生产针对CD4结合位点以外的表位的bNAb，最终与CD4bs bNAb结合进行预防和治疗。这一领域的进展将广泛影响以下战略：1)预防感染艾滋病毒的母亲传染给新生儿和哺乳婴儿；2)预防性传播艾滋病毒；3)对HIV-1感染者的治疗应用（包括消除潜伏库）。在最近的过去，多个研究小组已经确定并表征了针对HIV包膜的MPER和其他中和位点的新型广泛中和抗体。VRC将开发MPER单克隆抗体，并将其单独或作为联合方法的一部分推向临床。